Alnylam Pharmaceuticals Inc (ALNY)vsTango Therapeutics Inc (TNGX)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
TNGX
Tango Therapeutics Inc
$20.88
+7.19%
HEALTHCARE · Cap: $2.98B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 5853% more annual revenue ($3.71B vs $62.38M). ALNY leads profitability with a 8.5% profit margin vs -162.9%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
TNGX
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for TNGX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
No standout strengths identified
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Trading at 8.2x book value
0.0% earnings growth
ROE of -37.2% — below average capital efficiency
Revenue declined 100.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : TNGX
TNGX has a balanced fundamental profile.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : TNGX
The primary concerns for TNGX are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while TNGX is a turnaround play — different risk/reward profiles.
TNGX carries more volatility with a beta of 1.81 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 20/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Tango Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tango Therapeutics Inc. is a clinical-stage biotechnology company pioneering the development of targeted therapies aimed at addressing significant unmet needs in cancer treatment, particularly through the innovative concept of synthetic lethality. With a diverse pipeline of promising drug candidates, Tango is well-positioned to lead advancements in precision oncology, focusing on collaborative partnerships with leading research institutions to enhance its scientific capabilities. The company's strategic vision is to transform cancer care and improve patient outcomes, positioning it as a key player in the evolution of treatment paradigms in oncology.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?